Navigation Links
Doctors closer to using gene analysis to help trauma patients

actions to injury, including inflammation. The lead research author is Dr. J. Perren Cobb, an associate professor of surgery at Washington University in St. Louis.

Traumatic injuries claim hundreds of thousands of lives each year in the United States. In addition, millions of patients are hospitalized, at an annual cost to society of more than $200 billion. Patients may face a long and difficult recovery period riddled with many potentially fatal complications along the way.

“What we have shown is medical professionals can collect blood and tissue samples from patients, process them at different institutions and get consistent results,?said Henry Baker, associate director of the UF Genetics Institute and interim chairman of molecular genetics and microbiology. “For any tool used in clinical medicine, it’s important that people are able to get the same answers wherever the tool is being used.?/p>

Genomic analyses took place at UF, the Stanford Genome Technology Center and Washington University in St. Louis. Overall data analysis was based at Massachusetts General Hospital at Harvard Medical School.

Specially trained clinical personnel sampled whole blood and other available tissues from more than 200 severely traumatized or burned patients and 23 healthy individuals in an effort to correlate molecular markers with white blood cell behavior, and ultimately, with patient outcome. Studies in healthy patients were conducted at UF, Washington University in St. Louis, the University of Rochester School of Medicine and the University of Medicine and Dentistry of New Jersey. Patients with severe traumatic injuries were studied at the University of Washington at Seattle and the University of Rochester.

In the end, scientists could see dramatic changes in genes turning on and off in trauma victims compared with healthy people. Among the trauma patients, researchers say “analytical noise??differences attributable to the testing method ?was no
'"/>

Source:University of Florida


Page: 1 2 3

Related biology news :

1. Doctors should stop prescribing antibiotics for the common cold, review advises
2. New Discovery May Help Doctors Treat Infertility
3. Chemicals in tattoo inks need closer scrutiny
4. Proteomics brings researchers closer to understanding microbes that produce acid mine drainage
5. Scientists closer to new cancer detection method
6. Stroke treatment a step closer after trial
7. Sperm stem cells closer to being like embryonic stem cells
8. Scientists a step closer to protecting worlds most important crop
9. Scientists one step closer to cancer vaccine
10. UC Davis researchers move biotechnology closer to replacing electronic pacemakers
11. Producing bio-ethanol from agricultural waste a step closer

Post Your Comments:
(Date:11/20/2009)... , Chronic obstructive pulmonary disease (COPD), ...onchitis or emphysema, is the fourth leading cause... COPD and while researchers have yet to find any r...search Institute at The University of Western Onta...chniques to gain new insight into the disease. ...
(Date:11/19/2009)... , MADISON Leaf-cutter ants, which cultivate fun... Here,s a new one to add to the list: the ant farm...ogen-fixing bacteria to make their gardens grow. T...urnal Science , documents a previously unknown sy...ight into how leaf-cutter ants have come to domina...
(Date:11/19/2009)... , In a massive survey of genetic diversity in ma...ited States, have developed a gene map that should...nt that is a major source of food, fuel, animal fe...special type of gene map known as a haplotype map,... the genome of 27 inbred lines of maize. The resea...
Breaking Biology News(10 mins):Gaining a better picture of lung disease 2Like humans, ants use bacteria to make their gardens grow 2Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis 52567 1Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis 52567 2Injection Reverses Heart Attack Damage 4771 1Injection Reverses Heart Attack Damage 4771 2Injection Reverses Heart Attack Damage 4771 3American Joint Replacement Registry Announced 52562 1American Joint Replacement Registry Announced 52562 2
...ble in German . , Since Monday of this week, ... phase I trial in Neuss, Germany, where it is bein... is based on a vaccine that has been in use since ...nt infection with tuberculosis bacteria much more ...c basis for this was laid down by the team working...
...mber 11, 2008 People who are asked whether they w...ck might not follow their intentions when the snac...2008 issue of the Journal of Nutrition Education ...is a substantial inconsistency between healthful s...rticipants were asked about their intentions in ch...
...rease usability and adoption of SMS and mobile ...MENLO PARK, Calif., Sept. 10 Promptu Systems,Corp...owered mobile,applications, unveiled today at the ... accurate voice dictation system. Using the compan...CSSR(TM)) technology, the system converts,a user,s...
Other Biology News:Clinical trial for new tuberculosis vaccine 2Making snack food choices 2Promptu Unveils High Accuracy Voice-to-Text Dictation for Mobile Phones at CTIA 2
(Date:11/20/2009)...ILLE, Md., Nov. 20 Novav...has priced an underwritten public offering of 6,80... public of $3.30 per share. The approximately $21...rwriting discounts and commissions, will be used f...VLP-based vaccines, internal research and developm...
(Date:11/19/2009)...uld like to be able to charge their cell phones an...ften. A recent discovery made by UC San Diego engi...acitors that could do just this. , In recent re...abhakar Bandaru, a professor in the UCSD Departmen...ith graduate student Mark Hoefer, have found that ...
(Date:11/19/2009)...K, Nov. 19 NeoStem, Inc....ent the following letter to its shareholders, disc...009, of China Biopharmaceuticals Holdings, Inc. (C...ed in the People,s Republic of China. The merger g...Eyre Pharmaceutical Co. Ltd., CHBP,s primary opera...
(Date:11/19/2009)... Top LASIK surgeons and recognized refracti...LASIK Surgeons made brought their fellow surgeons ...rrection surgery, cataract surgery, and ophthalmol...Academy of Ophthalmology (AAO) annual meeting in S...r. Shachar Tauber, Dr. David Huang, MD, Dr. Randy ...
Breaking Biology Technology:Novavax Prices Public Offering of Common Stock 2Nanotube defects equal better energy and storage systems 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 9
...ccomplishments & 2008 Highlights Include: , ...t regulatory filings for new Bitter Blockers , , ...esignation for Sucralose Enhancer S2383, which all... , - New commercialization agreement for S2383 wit...ort regulatory filings for Sucrose (table sugar) E...
... Insurance Coverage of Hepatitis C Patients Is Ske...minance of Private Coverage in the General Populat...on Resources , , WALTHAM, Mass., Feb. 12 Decisio...nd advisory firms focusing on pharmaceutical and h...ient opportunity exists within many of the major U...
...TO, Calif., Feb. 12 BioMarin Pharmaceutical,Inc. ...t interim efficacy,analysis (IEA) for the Riquent(...oring Board (DMB) determined that the continuation...Jolla Pharmaceutical have decided to stop the,stud...al results including,secondary endpoints such as S...
Other Biology Technology:SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 2SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 3SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 4SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 5SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 6SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 7SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 8SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 9SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 10SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 11SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 12SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 13SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 14Hepatitis C Virus Patient Opportunity Exists Within Many of the Major U.S. Local Markets 2Hepatitis C Virus Patient Opportunity Exists Within Many of the Major U.S. Local Markets 3Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 2Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 3
Custom siRNA, HPLC purified, annealed from Ambion
Silencer Validated siRNA 5 nmol from Ambion
Mouse Anti-Cyclophilin D Monoclonal Antibody, Unconjugated, Clone PADZC006 from Invitrogen
Fok I from Promega
Biology Products: